SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Charlotte Brontë

PatientCharlotte Brontë
Date of birth1987-04-21
IdentifiersMRN HR-NI025-SYN; SSN (made up) 000-25-3804
Document date2026-02-24
AuthorEleanor Thwaite, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Prenatal visit at 13 weeks with the nuchal translucency scan. [S]

History of Present Illness

Ms. Brontë returns at 13 weeks 1 day. She vomits two or three times a week and eats three meals and two snacks a day. She has taken ondansetron about twice a day this week and doxylamine-pyridoxine four tablets a day. Constipation has settled with diet. Her PUQE-24 score is 7. She has begun writing again in the mornings. The cell-free DNA result came back last week as low risk for trisomies 21, 18, and 13. She had the nuchal translucency scan this morning. She has had no headache, pain, or bleeding. [S]

ElementDetail
Interval changeVomiting two or three times a week; three meals and two snacks a day
PUQE-247 (moderate), down from 9
ScreeningCell-free DNA low risk; nuchal translucency scan today
FunctionWriting again in the mornings

Review of Systems

SystemResultFinding
GastrointestinalPositiveMorning nausea; vomiting two or three times a week; bowels regular
NeurologicalNegativeNo headache
GenitourinaryNegativeNo bleeding or urinary symptoms
PsychiatricNegativeMood better; enjoying writing again

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe)One tablet by mouth dailyOral route2026-01-13activeS
Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, two tablets by mouth at bedtimeTwo tablets by mouth at bedtimeOral route2026-01-13 to 2026-01-20completedS
Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day)One tablet in the morning, one mid-afternoon, and two at bedtimeOral route2026-01-20activeS
Metoclopramide 10 mg oral tablet, one tablet by mouth three times a day before mealsOne tablet by mouth three times a day, 30 minutes before mealsOral route2026-01-20 to 2026-01-29completedS
Sodium chloride 0.9% with potassium chloride 20 mmol per liter, 1000 mL intravenously over 8 hours1000 mL over 8 hours, guided by daily electrolytesIntravenous route2026-01-29 to 2026-02-01completedS
Thiamine 100 mg intravenously daily, the first dose before any dextrose100 mg intravenously once daily; first dose before any dextrose-containing fluidIntravenous route2026-01-29 to 2026-02-01completedS
Ondansetron 4 mg intravenously every 8 hours4 mg by slow intravenous injection every 8 hoursIntravenous route2026-01-29 to 2026-02-01completedS
Enoxaparin 20 mg subcutaneously once daily during the admission (weight under 50 kg)20 mg (0.2 mL) subcutaneously once daily while in hospitalSubcutaneous route2026-01-29 to 2026-02-01completedS
Magnesium sulfate 2 g in 50 mL intravenously over 1 hour, once2 g intravenously over 1 hour, one doseIntravenous route2026-01-29 to 2026-01-29completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hoursOne tablet on the tongue every 8 hoursOral route2026-02-01 to 2026-02-24completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nauseaOne tablet on the tongue up to every 8 hours if neededOral route2026-02-24 to 2026-03-24completedS
Thiamine 100 mg oral tablet, one tablet by mouth three times a dayOne tablet by mouth three times a day while intake is poorOral route2026-02-01 to 2026-02-24completedS
Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtimeOne tablet by mouth at bedtime until deliveryOral route2026-02-24activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-02-24Body height152cmS
2026-02-24Body weight44.4kgS
2026-02-24Body mass index (BMI) [Ratio]19.2kg/m2S
2026-02-24Systolic blood pressure106mm[Hg]S
2026-02-24Diastolic blood pressure66mm[Hg]S
2026-02-24Heart rate82/minS
2026-02-24Respiratory rate14/minS
2026-02-24Body temperature36.6CelS
2026-02-24Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-24Fetal Crown Rump length US70mmConsistent with 13 weeks 1 day by the dating scanNormalS
2026-02-24Fetal nuchal translucency measured by US1.5mm<=3.5 mmNormalS

Physical Exam

Vital signs recorded on 2026-02-24; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 44.4 kg
AbdomenSoft; uterus palpable above the pubic bone
FetalScan this morning: single live fetus, crown-rump length 70 mm, nuchal translucency 1.5 mm, nasal bone present, no structural abnormality seen

Problems

ProblemClinical statusVerificationCodeProvenance
First pregnancy at 38 (elderly primigravida), single live intrauterine pregnancy dated by ultrasound at 7 weeks 1 dayactiveconfirmed O09.519S — Synthetic modern prenatal care anchored to the documented report that she was pregnant when she died; the pregnancy itself is questioned in one source (CLM-0019).
Nausea and vomiting of pregnancy, moderate (PUQE-24 score 10), with early weight loss, under evaluation for hyperemesis gravidarumresolvedconfirmed O21.9S — Synthetic presenting concern at the index visit, superseded by the hyperemesis gravidarum diagnosis at the sick visit; her documented "perpetual nausea" is D and the hyperemesis reading of it is R.
Hyperemesis gravidarum with metabolic disturbance: unable to keep fluids down, 7.4 percent weight loss, dehydration, hypokalemia, hyponatremia, hypochloremic alkalosis, low magnesium, and raised transaminases; PUQE-24 score 14activeconfirmed O21.1S — Synthetic modern diagnosis linked to her documented final illness and the retrospective hyperemesis interpretation; it is not asserted as her historical diagnosis.
Gestational transient thyrotoxicosis: suppressed TSH and mildly raised free T4 with hyperemesis, no goiter, eye signs, or tremor; no treatment neededactiveconfirmed O99.281S — Synthetic finding that teaches the thyroid tests in hyperemesis; it echoes no documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPUQE-24 score (recorded in the note; no LOINC code found)Every visit while nausea and vomiting lastCompleted today7 (moderate), down from 9
ExaminationWeight against pre-pregnancy weight (46.0 kg), pulse, blood pressure, and hydrationEvery visit while nausea and vomiting lastCompleted today44.4 kg, up 0.8 kg; pulse 82
LaboratoryElectrolytes, urea nitrogen, creatinine, and glucoseUntil stable on oral intakeNot indicatedNot repeated: normal two weeks ago and now eating regular meals
ImagingNuchal translucency scanOnce at 11 to 14 weeks, as she choseCompleted todayCrown-rump length 70 mm; nuchal translucency 1.5 mm
LaboratoryCell-free DNA screeningFrom 10 weeksCompleted todayLow risk for trisomies 21, 18, and 13, received last week
LaboratoryTSH and free T4In hyperemesis gravidarum; repeat at 16 to 18 weeks if suppressedDueRepeat planned at 16 to 18 weeks
Medication safetyAntiemetic effectsEvery visit and after each changeCompleted todayConstipation settled; ondansetron changed to as needed; thiamine stopped
Medication safetyLow-dose aspirinStart at 12 to 16 weeks with risk factors; review at every visitCompleted todayStarted today at 81 mg at bedtime; bleeding precautions given
ExaminationBlood pressureEvery prenatal visitCompleted today106/66 mmHg; baseline for aspirin and preeclampsia surveillance
ExaminationFetal heartEvery prenatal visitCompleted todayLive fetus on today's scan

Goal progress:

Guideline basis: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024); Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021)

Follow-up: Prenatal visit at 17 weeks, with TSH and free T4. Next scheduled visit 2026-03-24: prenatal visit at 17 weeks: nausea and vomiting review and thyroid recheck. [S]